Omeza offers OCM™, a drug-device combination product designed for all phases of wound healing, specifically targeting chronic wounds and venous leg ulcers. This proprietary technology enhances skin integrity and promotes healing through a personalized therapy approach administered by healthcare professionals.
Funding
$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic wounds, such as venous leg ulcers, present a significant challenge due to their slow healing rates and the complexities involved in addressing underlying issues that impede recovery. Traditional wound care methods may not always provide the comprehensive approach needed to effectively manage all phases of wound healing.
Solution
Omeza offers OCM™, a drug-device combination product designed to provide a comprehensive and personalized therapy for all phases of wound healing, with a specific focus on chronic wounds. This proprietary technology is administered by healthcare professionals and aims to enhance skin integrity and promote effective healing. OCM™ is designed to address the multifaceted issues commonly associated with chronic wounds, offering a novel approach to wound management.
Target Audience
The primary target audience includes healthcare professionals who treat patients with chronic wounds, as well as patients and caregivers seeking advanced wound care solutions.
Features
- Drug-device combination product for comprehensive wound healing.
- Designed for all phases of wound healing.
- Specifically targets chronic wounds and venous leg ulcers.
- Personalized therapy approach.
- Administered by healthcare professionals.
- Aims to enhance skin integrity.